下载PDF
{"title":"Transplantation Models to Characterize the Mechanisms of Stem Cell–Induced Islet Regeneration","authors":"Gillian I. Bell, Ayesh K. Seneviratne, Grace N. Nasri, David A. Hess","doi":"10.1002/9780470151808.sc02b04s26","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>This unit describes our current knowledge regarding the isolation human bone marrow–derived progenitor cells for the paracrine stimulation of islet regeneration after transplantation into immunodeficient mouse models of diabetes. By using high aldehyde dehydrogenase (ALDH<sup>hi</sup>) activity, a conserved function in multiple stem cell lineages, a mixed population of hematopoietic, endothelial, and mesenchymal progenitor cells can be efficiently purified using flow cytometry. We describe in vitro approaches to characterize and expand these distinct cell types. Importantly, these cell types can be transplanted into immunodeficient mice rendered beta-cell deficient by streptozotocin (STZ) treatment, in order monitor functional recovery from hyperglycemia and to characterize endogenous islet regeneration via paracrine mechanisms. Herein, we provide detailed protocols for: (1) isolation and characterization of ALDH<sup>hi</sup> cells for the establishment of hematopoietic and multipotent-stromal progenitor lineages; (2) intravenous and intrapancreatic transplantation of human stem cell subtypes for the quantification of glycemic recovery in STZ-treated immunodeficient mice; and (3) immunohistochemical characterization of islet recovery via the stimulation of islet neogenic, beta-cell proliferative, and islet revascularization programs. Collectively, these systems can be used to support the pre-clinical development of human progenitor cell–based therapies to treat diabetes via islet regeneration. <i>Curr. Protoc. Stem Cell Biol</i>. 26:2B.4.1-2B.4.35. © 2013 by John Wiley & Sons, Inc.</p></div>","PeriodicalId":53703,"journal":{"name":"Current Protocols in Stem Cell Biology","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/9780470151808.sc02b04s26","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Stem Cell Biology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/9780470151808.sc02b04s26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 4
引用
批量引用
Abstract
This unit describes our current knowledge regarding the isolation human bone marrow–derived progenitor cells for the paracrine stimulation of islet regeneration after transplantation into immunodeficient mouse models of diabetes. By using high aldehyde dehydrogenase (ALDHhi ) activity, a conserved function in multiple stem cell lineages, a mixed population of hematopoietic, endothelial, and mesenchymal progenitor cells can be efficiently purified using flow cytometry. We describe in vitro approaches to characterize and expand these distinct cell types. Importantly, these cell types can be transplanted into immunodeficient mice rendered beta-cell deficient by streptozotocin (STZ) treatment, in order monitor functional recovery from hyperglycemia and to characterize endogenous islet regeneration via paracrine mechanisms. Herein, we provide detailed protocols for: (1) isolation and characterization of ALDHhi cells for the establishment of hematopoietic and multipotent-stromal progenitor lineages; (2) intravenous and intrapancreatic transplantation of human stem cell subtypes for the quantification of glycemic recovery in STZ-treated immunodeficient mice; and (3) immunohistochemical characterization of islet recovery via the stimulation of islet neogenic, beta-cell proliferative, and islet revascularization programs. Collectively, these systems can be used to support the pre-clinical development of human progenitor cell–based therapies to treat diabetes via islet regeneration. Curr. Protoc. Stem Cell Biol . 26:2B.4.1-2B.4.35. © 2013 by John Wiley & Sons, Inc.
移植模型表征干细胞诱导的胰岛再生机制
本单元描述了我们目前关于分离人骨髓来源的祖细胞用于胰岛再生的旁分泌刺激移植到免疫缺陷的糖尿病小鼠模型的知识。利用高醛脱氢酶(ALDHhi)活性,一种多种干细胞谱系中的保守功能,流式细胞术可以有效地纯化造血、内皮和间充质祖细胞的混合群体。我们描述了体外方法来表征和扩展这些不同的细胞类型。重要的是,这些细胞类型可以移植到通过链脲佐菌素(STZ)治疗导致β细胞缺陷的免疫缺陷小鼠中,以监测高血糖后的功能恢复,并通过旁分泌机制表征内源性胰岛再生。在此,我们提供了详细的方案:(1)ALDHhi细胞的分离和表征,以建立造血和多能基质祖细胞谱系;(2)静脉和胰腺内移植人干细胞亚型,定量测定stz治疗免疫缺陷小鼠的血糖恢复情况;(3)通过刺激胰岛新生、β细胞增殖和胰岛血运重建计划来描述胰岛恢复的免疫组织化学特征。总的来说,这些系统可用于支持基于人类祖细胞的疗法的临床前开发,通过胰岛再生治疗糖尿病。咕咕叫。Protoc。干细胞生物学。26:2 . b .4.1- b .4.35。©2013 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。